A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES… (NCT07459634) | Clinical Trial Compass
Not Yet RecruitingPhase 2
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
United States50 participantsStarted 2026-06-12
Plain-language summary
The purpose of this study is to evaluate the efficacy and safety of lurbinectedin in combination with durvalumab for the treatment of participants with extensive stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first line (1L) induction therapy.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Participant has histologically or cytologically confirmed ES-SCLC (per Veterans Administration Lung Study Group staging system).
. Participant has received 4 cycles of definitive platinum-based chemotherapy with durvalumab
. Has Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
. Must have a life expectancy of ≥ 12 weeks as assessed by the treating physician.
. Adequate hematologic and end-organ function for at least 7 days prior to dosing.
. Has a body weight \> 30 kg.
. Adequate contraceptive precautions.
Exclusion criteria
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This is a Phase 2 trial combining lurbinectedin and durvalumab for extensive-stage small cell lung cancer — since it's only in Phase 2 and hasn't started recruiting yet, what do we actually know so far about how safe and effective this combination is compared to what's already available to me?
2The trial is 'not yet recruiting,' which means it could be months before I could even consider joining — given how quickly extensive-stage small cell lung cancer can progress, is waiting for this study to open a realistic option for my situation, or should we focus on starting treatment now?
3The main thing this trial is measuring is progression-free survival rate as assessed by the investigators — can you help me understand what that means in practical terms, and whether that's the outcome that matters most for someone in my position?
4Lurbinectedin and durvalumab are being combined here — are there known side effects from either drug individually that I should understand before deciding whether to discuss this trial further with you?
5If this trial does open and I were potentially eligible, how would participating affect my ability to access other treatments afterward if this combination stopped working?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
. Presence or history of Central Nervous System (CNS) metastases
. History of allogeneic organ transplantation.
. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on the screening chest CT scan.
. Any concurrent chemotherapy, study intervention, biologic, or hormonal therapy for cancer treatment.
. Receipt of live attenuated vaccine within 30 days prior to the first dose of study intervention.